Ascendis Pharma’s second-quarter sales fell short of expectations, with the company’s Yorvipath pricing coming in higher than anticipated. While the company faces challenges in the growth hormone market, analysts remain optimistic about the potential of Yorvipath in hypoparathyroidism and TransCon CNP in Achondroplasia.